Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 31 Jan 2011 |
| Orion sues Mylan in the U.S. to enforce its U.S. patent covering the proprietary drug Comtan® | 24 Jan 2011 |
| Orion invites analysts and media to Financial Statement Release conference on Wednesday 9 February 2011 | 20 Jan 2011 |
| Annual Summary of Stock Exchange Releases published in 2010 | 19 Jan 2011 |
| 79,866 Orion A-shares converted into B-shares | 14 Jan 2011 |